CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma

Pediatr Blood Cancer. 2005 Jul;45(1):68-71. doi: 10.1002/pbc.20315.

Abstract

We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34(+) peripheral blood stem cell transplantation (PBSCT). Fifteen stage 4 NBL patients underwent CD34(+) transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan. There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4-7 months after CD34(+) transplantation. Three of four patients died of CNS progressive disease at 2, 8, and 9 months after recurrence and the remaining single patient was lost to follow-up. CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD34*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms / epidemiology
  • Brain Neoplasms / pathology
  • Brain Neoplasms / secondary*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Incidence
  • Infant
  • Korea / epidemiology
  • Male
  • Neuroblastoma / epidemiology
  • Neuroblastoma / pathology
  • Neuroblastoma / secondary*
  • Neuroblastoma / therapy*
  • Peripheral Blood Stem Cell Transplantation*
  • Risk

Substances

  • Antigens, CD34